🇺🇸 FDA
Patent

US 10745352

Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

granted A61KA61K2300/00A61K31/404

Quick answer

US patent 10745352 (Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof) held by Shuttle Pharmaceuticals, Inc. expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Shuttle Pharmaceuticals, Inc.
Grant date
Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2300/00, A61K31/404, A61K31/573, A61K45/06